Description
BSE lists 3,71,000 new equity shares of Gujarat Terce Laboratories Limited issued on a preferential basis to promoters, effective February 25, 2026. Shares are subject to lock-in until June 16, 2027.
Summary
BSE has notified trading members that 3,71,000 new equity shares of Gujarat Terce Laboratories Limited (Scrip Code: 524314) are listed and permitted to trade on the Exchange effective Wednesday, February 25, 2026. These shares were issued on a preferential basis to promoters at Rs. 37.70 per share (face value Rs. 10 + premium Rs. 27.70).
Key Points
- 3,71,000 equity shares of Rs. 10/- each issued at a premium of Rs. 27.70 to promoters on a preferential basis
- Issue price: Rs. 37.70 per share
- Shares are ranking pari-passu with existing equity shares of the company
- Distribution numbers: 74,20,301 to 77,91,300
- Date of allotment: December 16, 2025
- ISIN: INE499G01013
- Trading effective from: February 25, 2026
Regulatory Changes
No regulatory changes introduced. This is a standard listing notification for newly allotted securities pursuant to a preferential issue.
Compliance Requirements
- Trading members must note the new securities listed under Scrip Code 524314
- The entire allotment of 3,71,000 shares is subject to lock-in and cannot be traded until June 16, 2027
- Lock-in applies to distribution numbers 74,20,301 to 77,91,300
Important Dates
- Date of Allotment: December 16, 2025
- Trading Commencement Date: February 25, 2026
- Lock-in Expiry Date: June 16, 2027
Impact Assessment
The listing of these preferential shares has minimal immediate market impact as all 3,71,000 shares are under lock-in until June 16, 2027, meaning they cannot be freely traded. The allotment increases the total share capital of Gujarat Terce Laboratories Limited. Broader market participants are unlikely to be affected; the primary implication is for the company’s promoter shareholding structure.
Impact Justification
Routine preferential allotment listing for a small number of shares to promoters with a lock-in period. Limited broader market impact as it affects a single small-cap company.